Korean J Hepatol.
2011 Mar;17(1):51-60. 10.3350/kjhep.2011.17.1.51.
Optimal technique and response of doxorubicin beads in hepatocellular cancer: bead size and dose
- Affiliations
-
- 1Division of Surgical Oncology, Department of Surgery, University of Louisville College of Medicine, Louisville, KY, USA. Robert.Martin@louisville.edu
- 2Department of Radiology, Clinica Vistahermosa, Alicante, Spain.
- 3Department of Radiology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
- 4Department of Radiology, Oncological Center under name of Blochin, Moscow, Russia.
- 5Department of Radiology, Regional Oncological Dispanser, Samara, Russia.
- 6Department of Radiology, Norton Healthcare Radiology, Louisville, KY, USA.
- 7Department of Interventional Radiology, University of Miami College of Medicine, Miami, FL, USA.
- KMID: 1105514
- DOI: http://doi.org/10.3350/kjhep.2011.17.1.51
Abstract
- BACKGROUND/AIMS
It has been shown that the drug-eluting beads loaded with doxorubicin (DEBDOX) are effective for the treatment of hepatocellular carcinoma (HCC). However, the optimal safety and efficacy still remain to be established by using various bead sizes, doxorubicin doses, and the degree of stasis.The aim of this study was to determine the optimal safety and efficacy of DEBDOX in the treatment of HCC.
METHODS
Analysis of a 503-patient prospective, multicenter, multinational Bead Registry Database from 2007 to 2010 identified 206 patients who had been treated for HCC with DEBDOX. Primary endpoints were to compare safety, tolerance, response rates, and overall survival based on bead size (100-300, 300-500, 500-700, and 700-900 microm), number of vials, doxorubicin dose, and degree of stasis.
RESULTS
In total, 206 patients underwent 343 treatments. The use of all four bead sizes was similar based on Child-Pugh class and Okuda stage, with a significantly higher use (50%) of beads of size 100-300 microm in patients with portal vein thrombosis (P=0.05). Significant differences were seen for the number of median treatments, median doxorubicin dose, lobar infusion), and degree of complete stasis. The rate of adverse events was higher for larger beads than for smaller beads (28% vs. 16%; P=0.02).
CONCLUSIONS
Bead size and dose may vary according to disease distribution. Smaller beads offer the opportunity for repeated treatments, a larger cumulative dose delivery, a lesser degree of complete stasis, and fewer adverse events.
Keyword
MeSH Terms
-
Adult
Aged
Aged, 80 and over
Antibiotics, Antineoplastic/*administration & dosage/adverse effects
Carcinoma, Hepatocellular/*drug therapy/mortality
Dose-Response Relationship, Drug
Doxorubicin/*administration & dosage/adverse effects
Drug Carriers/*chemistry
Female
Humans
Liver Neoplasms/*drug therapy/mortality
Male
Middle Aged
Particle Size
Prospective Studies
Severity of Illness Index
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarteral Chemoembolization: A Pilot Study
- Transarterial Chemoembolization Using Gelatin Sponges or Microspheres Plus Lipiodol-Doxorubicin versus Doxorubicin-Loaded Beads for the Treatment of Hepatocellular Carcinoma
- Culture of Rabbit Chondrocytes Using Chitosan Bead
- Comparison of Chemoembolization Outcomes Using 70–150 µm and 100–300 µm Drug-Eluting Beads in Treating Small Hepatocellular Carcinoma: A Korean Multicenter Study
- Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future
